Cousin David, Hummersone Marc G, Bradshaw Tracey D, Zhang Jihong, Moody Christopher J, Foreiter Magdalena B, Summers Helen S, Lewis William, Wheelhouse Richard T, Stevens Malcolm F G
Pharminox Ltd , Biocity , Pennyfoot St. , Nottingham NG1 1GF , UK.
School of Pharmacy , University of Nottingham , NG7 2RD , UK . Email:
Medchemcomm. 2018 Jan 19;9(3):545-553. doi: 10.1039/c7md00554g. eCollection 2018 Mar 1.
A series of 3-(benzyl-substituted)-imidazo[5,1-]-1,2,3,5-tetrazines () and related derivatives with 3-heteromethyl groups has been synthesised and screened for growth-inhibitory activity against two pairs of glioma cell lines with temozolomide-sensitive and -resistant phenotypes dependent on the absence/presence of the DNA repair protein -methylguanine-DNA methyltransferase (MGMT). In general the compounds had low inhibitory activity with GI values >50 μM against both sets of cell lines. Two silicon-containing derivatives, the TMS-methylimidazotetrazine () and the SEM-analogue (), showed interesting differences: compound () had a profile very similar to that of temozolomide with the MGMT+ cell lines being 5 to 10-fold more resistant than MGMT- isogenic partners; the SEM-substituted compound () showed potency across all cell lines irrespective of their MGMT status.
一系列3-(苄基取代)-咪唑并[5,1-]-1,2,3,5-四嗪()以及具有3-杂甲基的相关衍生物已被合成,并针对两对具有对替莫唑胺敏感和耐药表型的胶质瘤细胞系进行了生长抑制活性筛选,这些表型取决于DNA修复蛋白O6-甲基鸟嘌呤-DNA甲基转移酶(MGMT)的缺失/存在。总体而言,这些化合物对两组细胞系的抑制活性较低,GI值>50μM。两种含硅衍生物,即TMS-甲基咪唑并四嗪()和SEM类似物(),表现出有趣的差异:化合物()的情况与替莫唑胺非常相似,MGMT+细胞系比MGMT-同基因配对细胞系耐药5至10倍;SEM取代的化合物()在所有细胞系中均显示出活性,无论其MGMT状态如何。